The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Abstract
Immune 'checkpoint' inhibitors can increase the activity of tumor-resident cytotoxic lymphocytes and have revolutionized cancer treatment. Current therapies block inhibitory pathways in tumor-infiltrating CD8+ T cells and recent studies have shown similar programs in other effector populations such as natural killer (NK) cells. NK cells are critical for immunosurveillance, particularly the control of metastatic cells or hematological cancers. However, how NK cells specifically recognize transformed cells and dominant negative feedback pathways, as well as how tumors escape NK cell control, remains undefined. This review summarizes recent advances that have illuminated inhibitory checkpoints in NK cells, some of which are shared with conventional cytotoxic T lymphocytes. It also outlines emerging approaches aimed at unleashing the potential of NK cells in immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903474106 · Cited by 3,524
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
Braud, V. M., Allan, D. S. J., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., et al. (1998) · Nature · doi:10.1038/35869 · Cited by 2,227
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Yu, X., Harden, K., C Gonzalez, L., Francesco, M., Chiang, E., Irving, B., Tom, I., Ivelja, S., Refino, C. J., Clark, H., et al. (2009) · Nature Immunology · doi:10.1038/ni.1674 · Cited by 1,491
Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30700-9 · Cited by 1,399
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298
IL-12 family cytokines: immunological playmakers
Vignali, D. A. A., & Kuchroo, V. K. (2012) · Nature Immunology · doi:10.1038/ni.2366 · Cited by 1,297
IL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,221
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
Johnston, R. J., Comps-Agrar, L., Hackney, J., Yu, X., Huseni, M., Yang, Y., Park, S., Javinal, V., Chiu, H., Irving, B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.018 · Cited by 1,194
Tumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,183
Zhang, Q., Bi, J., Zheng, X., Chen, Y., Wang, H., Wu, W., Wang, Z., Wu, Q., Peng, H., Wei, H., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0132-0 · Cited by 1,122
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0085-8 · Cited by 1,021
Li, Y., Hermanson, D. L., Moriarity, B. S., & Kaufman, D. S. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.06.002 · Cited by 981
Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J., Wan, X., Lu, X., Reynolds, A., et al. (2018) · Leukemia · doi:10.1038/leu.2017.226 · Cited by 824
Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817
Yoshimura, A., Ohkubo, T., Kiguchi, T., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., Hara, T., & Miyajima, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07281.x · Cited by 753
Lin, J.-X., Migone, T.-S., Tseng, M., Friedmann, M., Weatherbee, J. A., Zhou, L., Yamauchi, A., Bloom, E. T., Mietz, J., John, S., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90141-8 · Cited by 752
Borrego, F., Ulbrecht, M., Weiss, E. H., Coligan, J. E., & Brooks, A. G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.5.813 · Cited by 727
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
Cytokines in Cancer Immunotherapy
Lee, S., & Margolin, K. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 693
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
Viel, S., Marçais, A., Guimaraes, F. S.-F., Loftus, R., Rabilloud, J., Grau, M., Degouve, S., Djebali, S., Sanlaville, A., Charrier, E., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aad1884 · Cited by 672
Self-citationTumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
Gao, Y., Souza-Fonseca-Guimaraes, F., Bald, T., Ng, S. S., Young, A., Ngiow, S. F., Rautela, J., Straube, J., Waddell, N., Blake, S. J., et al. (2017) · Nature Immunology · doi:10.1038/ni.3800 · Cited by 654
Self-citationDNAM-1, A Novel Adhesion Molecule Involved in the Cytolytic Function of T Lymphocytes
Shibuya, A., Campbell, D., Hannum, C., Yssel, H., Franz-Bacon, K., McClanahan, T., Kitamura, T., Nicholl, J., Sutherland, G. R., Lanier, L. L., et al. (1996) · Immunity · doi:10.1016/s1074-7613(00)70060-4 · Cited by 641
Biology and regulation of IL-2: from molecular mechanisms to human therapy
Spolski, R., Li, P., & Leonard, W. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0046-y · Cited by 637
Zhang, J.-G., Farley, A., Nicholson, S. E., Willson, T. A., Zugaro, L. M., Simpson, R. J., Moritz, R. L., Cary, D., Richardson, R., Hausmann, G., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2071 · Cited by 627
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Ribas, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0563 · Cited by 613
Marcus, A., Mao, A. J., Lensink-Vasan, M., Wang, L., Vance, R. E., & Raulet, D. H. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.016 · Cited by 611
Interleukin‐18: Biological properties and role in disease pathogenesis
Kaplanski, G. (2018) · Immunological Reviews · doi:10.1111/imr.12616 · Cited by 606
Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601
TGF-β – an excellent servant but a bad master
Kubiczkova, L., Sedlarikova, L., Hajek, R., & Sevcikova, S. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-183 · Cited by 511
TGF-β receptors: In and beyond TGF-β signaling
Vander Ark, A., Cao, J., & Li, X. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.09.002 · Cited by 469
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity
Ferrari de Andrade, L., Tay, R. E., Pan, D., Luoma, A. M., Ito, Y., Badrinath, S., Tsoucas, D., Franz, B., May, K. F., Harvey, C. J., et al. (2018) · Science · doi:10.1126/science.aao0505 · Cited by 459
Romagné, F., André, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson, D. M., Blaser, B. W., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206532 · Cited by 408
CIS is a potent checkpoint in NK cell–mediated tumor immunity
Delconte, R. B., Kolesnik, T. B., Dagley, L. F., Rautela, J., Shi, W., Putz, E. M., Stannard, K., Zhang, J.-G., Teh, C., Firth, M., et al. (2016) · Nature Immunology · doi:10.1038/ni.3470 · Cited by 384
Self-citationAnti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382
Cutting Edge: Priming of NK Cells by IL-18
Chaix, J., Tessmer, M. S., Hoebe, K., Fuséri, N., Ryffel, B., Dalod, M., Alexopoulou, L., Beutler, B., Brossay, L., Vivier, E., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1627 · Cited by 374
Goldberg, M. V., & Drake, C. G. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_114 · Cited by 337
Cortez, V. S., Ulland, T. K., Cervantes-Barragan, L., Bando, J. K., Robinette, M. L., Wang, Q., White, A. J., Gilfillan, S., Cella, M., & Colonna, M. (2017) · Nature Immunology · doi:10.1038/ni.3809 · Cited by 332
Vari, F., Arpon, D., Keane, C., Hertzberg, M. S., Talaulikar, D., Jain, S., Cui, Q., Han, E., Tobin, J., Bird, R., et al. (2018) · Blood · doi:10.1182/blood-2017-07-796342 · Cited by 313
Sharma, A., Subudhi, S. K., Blando, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 312
Tahara-Hanaoka, S. (2004) · International Immunology · doi:10.1093/intimm/dxh059 · Cited by 286
Kohrt, H. E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuseri, N., Bonnafous, C., Czerwinski, D., Rajapaksa, A., et al. (2014) · Blood · doi:10.1182/blood-2013-08-519199 · Cited by 283
Huntington, N. D., Puthalakath, H., Gunn, P., Naik, E., Michalak, E. M., Smyth, M. J., Tabarias, H., Degli-Esposti, M. A., Dewson, G., Willis, S. N., et al. (2007) · Nature Immunology · doi:10.1038/ni1487 · Cited by 268
Self-citationAdoptive Immunotherapy for Cancer or Viruses
Maus, M. V., Fraietta, J. A., Levine, B. L., Kalos, M., Zhao, Y., & June, C. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120136 · Cited by 264
NKG2A Complexed with CD94 Defines a Novel Inhibitory Natural Killer Cell Receptor
Brooks, A. G., Posch, P. E., Scorzelli, C. J., Borrego, F., & Coligan, J. E. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.4.795 · Cited by 262
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Mehta, R. S., & Rezvani, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00283 · Cited by 259
A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
Deng, W., Gowen, B. G., Zhang, L., Wang, L., Lau, S., Iannello, A., Xu, J., Rovis, T. L., Xiong, N., & Raulet, D. H. (2015) · Science · doi:10.1126/science.1258867 · Cited by 255
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Du, X., Tang, F., Liu, M., Su, J., Zhang, Y., Wu, W., Devenport, M., Lazarski, C. A., Zhang, P., Wang, X., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0011-0 · Cited by 249
Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15
Ring, A. M., Lin, J.-X., Feng, D., Mitra, S., Rickert, M., Bowman, G. R., Pande, V. S., Li, P., Moraga, I., Spolski, R., et al. (2012) · Nature Immunology · doi:10.1038/ni.2449 · Cited by 248
CD3/TCR complex‐associated lymphocyte activation gene‐3 molecules inhibit CD3/TCR signaling
Hannier, S., Tournier, M., Bismuth, G., & Triebel, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4058 · Cited by 248
Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Ochoa, M. C., Minute, L., Rodriguez, I., Garasa, S., Perez‐Ruiz, E., Inogés, S., Melero, I., & Berraondo, P. (2017) · Immunology & Cell Biology · doi:10.1038/icb.2017.6 · Cited by 230
IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity
Molgora, M., Bonavita, E., Ponzetta, A., Riva, F., Barbagallo, M., Jaillon, S., Popović, B., Bernardini, G., Magrini, E., Gianni, F., et al. (2017) · Nature · doi:10.1038/nature24293 · Cited by 226
Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
Daher, M., & Rezvani, K. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.013 · Cited by 224
Benson, D. M., Bakan, C. E., Zhang, S., Collins, S. M., Liang, J., Srivastava, S., Hofmeister, C. C., Efebera, Y., Andre, P., Romagne, F., et al. (2011) · Blood · doi:10.1182/blood-2011-06-360255 · Cited by 208
Adoptive T-Cell Therapy for Cancer
Yang, J. C., & Rosenberg, S. A. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.006 · Cited by 206
Sarhan, D., Cichocki, F., Zhang, B., Yingst, A., Spellman, S. R., Cooley, S., Verneris, M. R., Blazar, B. R., & Miller, J. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0839 · Cited by 200
CD 155, an onco‐immunologic molecule in human tumors
Gao, J., Zheng, Q., Xin, N., Wang, W., & Zhao, C. (2017) · Cancer Science · doi:10.1111/cas.13324 · Cited by 199
Pasero, C., Gravis, G., Granjeaud, S., Guerin, M., Thomassin-Piana, J., Rocchi, P., Salem, N., Walz, J., Moretta, A., & Olive, D. (2015) · Oncotarget · doi:10.18632/oncotarget.3965 · Cited by 195
Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells
Sathe, P., Delconte, R. B., Souza-Fonseca-Guimaraes, F., Seillet, C., Chopin, M., Vandenberg, C. J., Rankin, L. C., Mielke, L. A., Vikstrom, I., Kolesnik, T. B., et al. (2014) · Nature Communications · doi:10.1038/ncomms5539 · Cited by 187
Self-citationNovel TGF-β inhibitors ready for prime time in onco-immunology
de Gramont, A., Faivre, S., & Raymond, E. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1257453 · Cited by 183
Benson, D. M., Cohen, A. D., Jagannath, S., Munshi, N. C., Spitzer, G., Hofmeister, C. C., Efebera, Y. A., Andre, P., Zerbib, R., & Caligiuri, M. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0304 · Cited by 180
Robertson, M. J., Cameron, C. A., Atkins, M. B., Gordon, M. S., Lotze, M. T., Sherman, M. L., & Ritz, J. (1999) · PubMed · Cited by 171
Natural killer cells in inflammation and autoimmunity
Zitti, B., & Bryceson, Y. T. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.08.001 · Cited by 164
Laurent, S., Queirolo, P., Boero, S., Salvi, S., Piccioli, P., Boccardo, S., Minghelli, S., Morabito, A., Fontana, V., Pietra, G., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-108 · Cited by 163
NKG2D Ligands–Critical Targets for Cancer Immune Escape and Therapy
Schmiedel, D., & Mandelboim, O. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02040 · Cited by 163
PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients
Concha-Benavente, F., Kansy, B., Moskovitz, J., Moy, J., Chandran, U., & Ferris, R. L. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0062 · Cited by 161
Pehlivan, K. C., Duncan, B. B., & Lee, D. W. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0470-x · Cited by 153
Chockley, P. J., Chen, J., Chen, G., Beer, D. G., Standiford, T. J., & Keshamouni, V. G. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97611 · Cited by 151
Vey, N., Karlin, L., Sadot‐Lebouvier, S., Broussais, F., Berton-Rigaud, D., Rey, J., Charbonnier, A., Marie, D., André, P., Paturel, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24832 · Cited by 149
Locatelli, F., Pende, D., Falco, M., Chiesa, M. D., Moretta, A., & Moretta, L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.009 · Cited by 149
Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
Ben‐Shmuel, A., Biber, G., & Barda‐Saad, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00275 · Cited by 146
Davis, Z., Vallera, D. A., Miller, J. S., & Felices, M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.07.011 · Cited by 143
The biology and mechanism of action of suppressor of cytokine signaling 3
Babon, J. J., & Nicola, N. A. (2012) · Growth Factors · doi:10.3109/08977194.2012.687375 · Cited by 142
Natural killer cell education in human health and disease
Boudreau, J. E., & Hsu, K. C. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.11.003 · Cited by 137
Johnston, J. A., Wang, L.-M., Hanson, E. P., Sun, X., White, M. F., Oakes, S. A., Pierce, J. H., & O’Shea, J. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.48.28527 · Cited by 134
TGF-β Inhibition and Immunotherapy: Checkmate
Ganesh, K., & Massagué, J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.037 · Cited by 126
Aptsiauri, N., Ruiz‐Cabello, F., & Garrido, F. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.006 · Cited by 125
Oei, V. Y. S., Kłopotowska, M., Graczyk‐Jarzynka, A., Hoel, H. J., Yang, W., Palacios, D., Almåsbak, H., Bajor, M., Clement, D., Brandt, L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0207 · Cited by 109
Mollanoori, H., Shahraki, H., Rahmati, Y., & Teimourian, S. (2018) · Human Immunology · doi:10.1016/j.humimm.2018.09.007 · Cited by 109
The unconventional expression of IL‐15 and its role in NK cell homeostasis
Huntington, N. D. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.1 · Cited by 105
Self-citationRevisiting Interleukin-12 as a Cancer Immunotherapy Agent
Berraondo, P., Etxeberría, I., Ponz‐Sarvisé, M., & Melero, I. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0381 · Cited by 96
Verdeil, G., Puthier, D., Nguyen, C., Schmitt‐Verhulst, A., & Auphan‐Anezin, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4834 · Cited by 95
Li, B., Jiang, Y., Li, G., Fisher, G. A., & Li, R. (2020) · JCI Insight · doi:10.1172/jci.insight.136570 · Cited by 94
Bench to bedside: NK cells and control of metastasis
Krasnova, Y., Putz, E. M., Smyth, M. J., & Souza-Fonseca-Guimarães, F. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.10.001 · Cited by 90
Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade
Ohs, I., Ducimetière, L., Marinho, J. C. L., Kulig, P., Becher, B., & Tugues, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1032 · Cited by 88
Therapeutic blockade of activin-A improves NK cell function and antitumor immunity
Rautela, J., Dagley, L. F., de Oliveira, C. C., Schuster, I. S., Hediyeh-zadeh, S., Delconte, R. B., Cursons, J., Hennessy, R. J., Hutchinson, D. S., Harrison, C. A., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aat7527 · Cited by 83
Self-citationFujii, R., Jochéms, C., Tritsch, S. R., Wong, H. C., Schlom, J., & Hodge, J. W. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2121-4 · Cited by 82
A Transcriptional Program for Detecting TGFβ-Induced EMT in Cancer
Foroutan, M., Cursons, J., Hediyeh-zadeh, S., Thompson, E. W., & Davis, M. J. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0313 · Cited by 81
Self-citationSullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L. A., Gajewski, T. F., Gastman, B., Lawson, D. H., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0362-6 · Cited by 81
Activin-A attenuates several human natural killer cell functions
Robson, N. C., Wei, H., McAlpine, T., Kirkpatrick, N., Cebon, J. S., & Maraskovsky, E. (2009) · Blood · doi:10.1182/blood-2008-07-166926 · Cited by 76
The global landscape of cancer cell therapy
Tang, J., Hubbard-Lucey, V. M., Pearce, L., O’Donnell-Tormey, J., & Shalabi, A. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.74 · Cited by 74
Overcoming hypoxia-induced functional suppression of NK cells
Solocinski, K., Padget, M. R., Fabian, K. P., Wolfson, B., Cecchi, F., Hembrough, T., Benz, S. C., Rabizadeh, S., Soon‐Shiong, P., Schlom, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000246 · Cited by 69
Mechanisms of Resistance to NK Cell Immunotherapy
Sordo‐Bahamonde, C., Vitale, M., Lorenzo‐Herrero, S., López‐Soto, A., & Gonzalez, S. R. (2020) · Cancers · doi:10.3390/cancers12040893 · Cited by 67
Norell, H., Carlsten, M., Ohlum, T., Malmberg, K., Masucci, G. V., Schedvins, K., Altermann, W., Handke, D., Atkins, D., Seliger, B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0029 · Cited by 66
Thaker, P. H., Brady, W. E., Lankes, H. A., Odunsi, K. O., Bradley, W. H., Moore, K. N., Muller, C. Y., Anwer, K., Schilder, R. J., Alvarez, R. D., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.08.001 · Cited by 66
Bisheshar, S. K., de Ruiter, E. J., Devriese, L. A., & Willems, S. M. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1747345 · Cited by 58
Locus-Specific Analysis of Human Leukocyte Antigen Class I Expression in Melanoma Cell Lines
Marincola, F. M., Shamamian, P. E., Simonis, T. B., Abati, A. D., Hackett, J., Dea, T. O., Fetsch, P. A., Yannelli, J. R., Restifo, N. P., Mulé, J. J., et al. (1994) · Journal of Immunotherapy · doi:10.1097/00002371-199407000-00002 · Cited by 52
Park, H. S., Cho, U., Im, S. Y., Yoo, C. Y., Jung, J. H., Suh, Y. J., & Choi, H. J. (2018) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2018.10.11 · Cited by 41
Vey, N., Dumas, P., Récher, C., Gastaud, L., Lioure, B., Bulabois, C., Pautas, C., Marolleau, J., Leprêtre, S., Raffoux, E., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.889.889 · Cited by 40
Sottile, R., Pangigadde, P., Tan, T., Anichini, A., Sabbatino, F., Trecroci, F., Favoino, E., Orgiano, L., Roberts, J. T., Ferrone, S., et al. (2015) · European Journal of Immunology · doi:10.1002/eji.201445289 · Cited by 38
Molecular insight into targeting the NK cell immune response to cancer
Rautela, J., Souza-Fonseca-Guimarães, F., Hediyeh-zadeh, S., Delconte, R. B., Davis, M. J., & Huntington, N. D. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12045 · Cited by 32
Self-citationEfficient genome editing of human natural killer cells by CRISPR RNPPreprint
Rautela, J., Surgenor, E. E., & Huntington, N. D. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/406934 · Cited by 32
Self-citationHigh-Risk Leukemia: Past, Present, and Future Role of NK Cells
Mavers, M., & Bertaina, A. (2018) · Journal of Immunology Research · doi:10.1155/2018/1586905 · Cited by 29
The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies
Stein, N., Tsukerman, P., & Mandelboim, O. (2016) · Human Antibodies · doi:10.3233/hab-160307 · Cited by 22
Felices, M., Sarhan, D., Brandt, L., Guldevall, K., McElmurry, R. T., Lenvik, A. J., Chu, S., Tolar, J., Taras, E. P., Spellman, S. R., et al. (2016) · Blood · doi:10.1182/blood.v128.22.4291.4291 · Cited by 11
Visan, I. (2018) · Nature Immunology · doi:10.1038/s41590-018-0076-4 · Cited by 10
A natural killer cell gene signature predicts melanoma patient survivalPreprint
Cursons, J., Souza-Fonseca-Guimarães, F., Anderson, A., Foroutan, M., Hediyeh-zadeh, S., Behren, A., Huntington, N. D., & Davis, M. J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/375253 · Cited by 7
Self-citation
Cited by
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01048-4 · Cited by 1,687
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
Maynard, A., McCoach, C. E., Rotow, J. K., Harris, L., Haderk, F., Kerr, D. L., Yu, E. A., Schenk, E. L., Tan, W., Zee, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.017 · Cited by 685
The cancer–natural killer cell immunity cycle
Huntington, N. D., Cursons, J., & Rautela, J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0272-z · Cited by 566
Self-citation
Metadata
- Authors
- Souza-Fonseca-Guimaraes, F., Cursons, J., & Huntington, N. D.
- Venue
- Trends in Immunology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 40
- Issue
- 2
- Pages
- 142-158
- ISSN
- 1471-4906 (ISSN-L)
- OpenAlex
- W2909660453
- Cited by
- 279
- References
- 117
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.